<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002863'>Myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) are clonal stem cell <z:e sem="disease" ids="C1521860" disease_type="Disease or Syndrome" abbrv="">hematologic disorders</z:e> that evolve to <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) and thus model multistep <z:e sem="disease" ids="C0598766" disease_type="Neoplastic Process" abbrv="">leukemogenesis</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Activating <z:mp ids='MP_0011356'>RAS</z:mp> mutations and overexpression of BCL-2 are prognostic features of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> transformation </plain></SENT>
<SENT sid="2" pm="."><plain>Using NRASD12 and BCL-2, we created two distinct models of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, where human (h)BCL-2 is conditionally or constitutively expressed </plain></SENT>
<SENT sid="3" pm="."><plain>Our novel transplantable in vivo models show that expression of hBCL-2 in a primitive compartment by mouse <z:e sem="disease" ids="C1458155" disease_type="Neoplastic Process" abbrv="">mammary tumor</z:e> virus-long terminal repeat results in a disease resembling human <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, whereas the myeloid MRP8 promoter induces a disease with characteristics of human <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Expanded leukemic stem cell (Lin(-)/Sca-1(+)/c-Kit(+)) populations and hBCL-2 in the increased <z:mp ids='MP_0011356'>RAS</z:mp>-<z:chebi fb="11" ids="15996">GTP</z:chebi> complex within the expanded Sca-1(+) compartment are described in both <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-like diseases </plain></SENT>
<SENT sid="5" pm="."><plain>Furthermore, the oncogenic compartmentalizations provide the proapoptotic versus antiapoptotic mechanisms, by activating extracellular signal-regulated kinase and AKT signaling, in determination of the neoplastic phenotype </plain></SENT>
<SENT sid="6" pm="."><plain>When hBCL-2 is switched off with <z:chebi fb="1" ids="50845">doxycycline</z:chebi> in the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> mice, partial reversal of the phenotype was observed with persistence of bone marrow blasts and tissue infiltration as <z:mp ids='MP_0011356'>RAS</z:mp> recruits endogenous mouse (m)BCL-2 to remain active, thus demonstrating the role of the complex in the disease </plain></SENT>
<SENT sid="7" pm="."><plain>This represents the first in vivo progression model of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> dependent on the formation of a BCL-2:<z:mp ids='MP_0011356'>RAS</z:mp>-<z:chebi fb="11" ids="15996">GTP</z:chebi> complex </plain></SENT>
<SENT sid="8" pm="."><plain>The colocalization of BCL-2 and <z:mp ids='MP_0011356'>RAS</z:mp> in the bone marrow of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients offers targeting either oncogene as a therapeutic strategy </plain></SENT>
</text></document>